OasisLMS

In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer.

Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-generation sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  
• Stephen Liu, MD, Chief, Hematology & Oncology, Head, Developmental Therapeutics, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

• Byoung Chul Cho, MD, PhD, Professor, Division of Medical Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, South Korea
• Igor Odintsov, MD, Instructor, Harvard Medical School, Associate Pathologist, Brigham and Women's Hospital, Boston, MA, USA
• Sulin Wu, MD, PhD, ABMGG Diplomate, Fellow, Section of Hematology and Oncology, Department of Medicine, University of Chicago, IL, USA